Vera Therapeutics (VERA) Restructuring Costs (2020 - 2021)
Vera Therapeutics posted quarterly Restructuring Costs of -$116000.0 for Q4 2021, down 107.34% year-on-year from $1.6 million in Q4 2020, and down 474.19% on a QoQ basis from $31000.0 in Q3 2021.
Vera Therapeutics (VERA) has 2 years of Restructuring Costs data on file, last reported at -$116000.0 in Q4 2021.
- For the quarter ending Q4 2021, Restructuring Costs fell 107.34% year-over-year to -$116000.0; the trailing twelve-month figure through Dec 2021 stood at $2.9 million (changed N/A YoY), and the FY2020 full-year result was $3.0 million, changed N/A from the prior year.
- Restructuring Costs for Q4 2021 stood at -$116000.0, down from $31000.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $1.6 million in Q4 2020 and bottomed at -$116000.0 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vera Therapeutics | 2.43 Bn | 1.83 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -116,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Dec 31, 2020 | 1.58 Mn |
| Sep 30, 2020 | 1.42 Mn |